



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





## Breast NGS Fusion Panel

### Alternative Name

Breast Fusion Panel

### Methodology

Molecular

### Test Description

The Breast NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ACTL6A, AKT3, BRAF, CAPZA2, CCDC170, CCDC6, COA5, CTNNB1, ESR1, ETV5, FGFR3, KIAA1549, MAST1, MAST2, MET, MYB, NCOA4, NFIB, NOTCH1, NOTCH2, NTRK1, NTRK2, NTRK3, PIK3CA, RAF1, RASGEF1A, RET, RPS6KC1, and TACC3.

### Clinical Significance

The Breast NGS Fusion Panel identifies the recurrent, targetable gene fusions in breast cancer for the purposes of prognosis and treatment management.

Managing the aggressive forms of breast cancer remains a challenge despite many targeted therapy approaches. Studies have shown that gene fusions may have become a precision medicine approach for the disease. Oncogenic fusions in ER-positive breast cancer may function as predictive biomarkers of clinical resistance to endocrine therapy. Fusion genes may in themselves be a biomarker of advanced and aggressive disease and are associated with some potentially targetable protein kinases. NTRK fusions are rare, but testing is of high interest due to possible treatment with specific TRK inhibitors (entrectinib, larotrectinib).

### Specimen Requirements

- **FFPE tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

### Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

### CPT Code(s)\*

81449

### Medicare MoIDX CPT Code(s)\*

81449

### New York Approved

Yes

### Level of Service

Global

## Turnaround Time

21 Days

## References

1. Natrajan, R. et al. Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. *Cancer Discov*; 8(3); 272–5. ©2018 AACR.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 052024